T4090 vs Rhopressa for Glaucoma
Recruiting at 22 trial locations
CL
JH
Overseen ByJames H. Peace
Age: 18+
Sex: Any
Trial Phase: Phase 2
Sponsor: Laboratoires Thea
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial
Trial Summary
What is the purpose of this trial?
The main purpose is to compare the ocular hypotensive efficacy and safety of two concentrations of T4090 (Kinezodianone R HCl 0.2% and 0.3%) ophthalmic solution with Rhopressa® ophthalmic solution
Eligibility Criteria
This trial is for adults over 18 with Open-Angle Glaucoma or Ocular Hypertension in both eyes. Participants must understand the study and sign a consent form.Inclusion Criteria
Informed consent dated and signed.
I am 18 years old or older.
I have been diagnosed with glaucoma or high eye pressure in both eyes.
Exclusion Criteria
I have a specific type of glaucoma not caused by an eye injury.
My glaucoma is in an advanced stage.
I have not had eye trauma, infection, or significant inflammation in the last 6 months.
See 2 more
Treatment Details
Interventions
- Rhopressa®
- T4090
Trial OverviewThe trial aims to compare the effectiveness and safety of two concentrations (0.2% and 0.3%) of T4090 ophthalmic solution against Rhopressa® in reducing eye pressure.
Participant Groups
3Treatment groups
Experimental Treatment
Active Control
Group I: T4090 0.3%Experimental Treatment1 Intervention
Group II: T4090 0.2%Experimental Treatment1 Intervention
Group III: Rhopressa®Active Control1 Intervention
Find a Clinic Near You
Who Is Running the Clinical Trial?
Laboratoires Thea
Lead Sponsor
Trials
64
Recruited
6,900+
Other People Viewed
By Subject
By Trial
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.